What started in 2002 with a small team and a handful of clients has grown into a global preclinical CRO trusted by more than 400 clients worldwide, including many leading pharmaceutical and biotechnology companies. Our commitment to delivering bespoke and standard study designs in a quick, expert, and cost-effective manner has allowed us to support more than 1,000 studies per year for multiple consecutive years, something we are incredibly proud of. Over the years, we have been fortunate to contribute data supporting numerous marketed drugs, numerous successful client acquisitions, and programmes successfully supporting patients. Most importantly, our success is a testament to the wider scientific community and the innovative ideas and projects our clients trust us to support every day. Thank you to every client, collaborator, colleague, and friend who has been part of our journey so far. We look forward to supporting the next generation of science and innovation for another 24 years.

We are delighted to announce the promotion of Dr. Martin Barrett to Chief Business Officer at Pharmidex . Martin brings more than 23 years of experience across the pharmaceutical and drug discovery sectors, combining deep scientific expertise with strategic commercial leadership. Throughout his career, he has played a key role in advancing translational science, building strategic partnerships and supporting innovative drug development programmes. In his new role, Martin will help drive Pharmidex’s continued growth, strengthen collaborations, and expand our capabilities across preclinical pharmacology, toxicology, translational science, and clinical development support. Congratulations to Martin on this well-deserved promotion. We look forward to the continued impact of his leadership across Pharmidex and the wider drug discovery community.